A Combination of Antigenic Regions of Toxoplasma gondii Microneme Proteins Induces Protective Immunity against Oral Infection with Parasite Cysts

Infection with Toxoplasma gondii causes morbidity and mortality in congenitally infected and immunocompromised individuals. Both humoral and cell-mediated immunity are involved in host resistance to invasion of the parasite. Among putative vaccine candidates, the T. gondii microneme proteins appear...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 191; no. 4; pp. 637 - 645
Main Authors: Beghetto, Elisa, Nielsen, Henrik V., Porto, Paola Del, Buffolano, Wilma, Guglietta, Silvia, Felici, Franco, Petersen, Eskild, Gargano, Nicola
Format: Journal Article
Language:English
Published: Chicago, IL The University of Chicago Press 15-02-2005
University of Chicago Press
Oxford University Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infection with Toxoplasma gondii causes morbidity and mortality in congenitally infected and immunocompromised individuals. Both humoral and cell-mediated immunity are involved in host resistance to invasion of the parasite. Among putative vaccine candidates, the T. gondii microneme proteins appear to be promising, because they are responsible for the invasion process. The present work focused on studying the immunogenicity of microneme proteins in infected individuals and in a mouse model of chronic toxoplasmosis. We identified 5 distinct antigenic regions within MIC2, MIC4, MIC2-associated protein, and apical membrane antigen 1 gene products, which were recognized by (1) T cells from both adults with acquired infection and children with congenital infection and (2) antibodies from all patients. Finally, we demonstrated that DNA immunization with microneme fragments elicited effective protection in mice (84% reduction in brain-cyst burden), suggesting that a combination of these antigenic regions should be considered in the design of potential vaccines against toxoplasmosis.
Bibliography:istex:B549133ADF4D88BAF297F06585283577D07B20E0
ark:/67375/HXZ-3RZR92SQ-Z
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1086/427660